3 results
Approved WMOCompleted
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
Approved WMOCompleted
Primary objective: To evaluate the optimum comfortable on-demand humidification doses for neuromuscular patients requiring chronic mechanical ventilation using subjective as well as objective measurements of the optimum comfort.
Approved WMOCompleted
Obtain safety and efficacy data for the investigational drug AMB-05X in the treatment of tenosynovial giant cell tumor (TGCT)